Due out this spring. PC demo now available. Dark forces are drawn to the lands of Terrinoth. Yet somewhere lies a forgotten relic that could turn the tides. Such power cannot fall into the wrong hands ...
Terrinoth: Heroes Of Descent is a high fantasy tactical RPG that brings the legendary Descent tabletop universe as a video game for the first time. Terrinoth: Heroes Of Descent combines real-time ...
Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...
SEATTLE--(BUSINESS WIRE)--Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and ...
In The Descent, an outdoor adventure goes terribly wrong for six friends who enter caves looking for fun but find murderous creatures within the depths. Jen Karner has spent the last 10 years covering ...
Recursive language models (RLMs) are an inference technique developed by researchers at MIT CSAIL that treat long prompts as an external environment to the model. Instead of forcing the entire prompt ...
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results